A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease

OBJECTIVE: To study efficacy and safety of escalating doses of canakinumab, a fully human anti-IL-1β monoclonal antibody in the severe cryopyrin-associated periodic syndrome, neonatal-onset multisystem inflammatory disease (NOMID). METHODS: 6 patients were enrolled in this 24-month, open-label phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Sibley, Cailin H, Chioato, Andrea, Felix, Sandra, Colin, Laurence, Chakraborty, Abhijit, Plass, Nikki, Rodriguez-Smith, Jackeline, Brewer, Carmen, King, Kelly, Zalewski, Christopher, Kim, H Jeffrey, Bishop, Rachel, Abrams, Ken, Stone, Deborah, Chapelle, Dawn, Kost, Bahar, Snyder, Christopher, Butman, John A, Wesley, Robert, Goldbach-Mansky, Raphaela
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4258169/
https://ncbi.nlm.nih.gov/pubmed/24906637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2013-204877
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados